02696 HENLIUS
- 18.840
- 0.0000.00%
HENLIUS News
Express News | Sermonix Pharmaceuticals- Agreement Also Allows Henlius to Share With Sermonix Expedited Co-Development of Oral Lasofoxifene in Japan
Express News | Sermonix Pharmaceuticals-This Month,Henlius Expanded License From Sermonix to Add Additional Asia Territories for Upfront, Milestone, Royalty Payments
Express News | Sermonix Pharmaceuticals- Sermonix and Henlius Will Engage With Pmda and Collaborate on Expedited Co-Development of Oral Lasofoxifene in Japan
Express News | Sermonix Pharmaceuticals- Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
[Hong Kong Stock Connect] It is reported that Fosun Pharmaceutical (02196) plans to privatize its subsidiary Fuhong Hanlin (02696)
Jinwu Financial News | A report quoted people familiar with the matter as saying that Fosun Pharmaceuticals (02196) is considering privatizing its subsidiary Fuhong Hanlin (02696) and is cooperating with a consulting firm on a potential privatization offer; other investors may also participate in the deal. The report said that negotiations are ongoing, but they will not necessarily lead to a deal. Fuhong Hanlin suspended trading on May 23.
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator
Shanghai Henlius Biotech (HKG:2696) said its marketing authorization applications for HLX14 as a biosimilar of Prolia and Xgeva have been validated by the European Medicines Agency, according to a Fri
Organon Says European Medicines Agency (Ema) Validates Henlius And Organon Filings For Prolia And Xgeva (Denosumab) Biosimilar Candidate HlX14
Company announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia and Xgeva (denosumab) biosimilar. Denosuma
Henlius Biotech's HLX14 Biosimilar Advances in Europe
Fu Hong Han Lin (02696.HK): The marketing license application (MaaS) for the desumab antibiotic analogue HLX14 was accepted by the European Medicines Agency (EMA)
Gelonghui, May 24, 丨 Fu Hong Hanlin (02696.HK) announced that recently, two marketing license applications (MaaS) for the Prolia and Xgeva (desumab) biosimilar HLX14 (recombinant anti-RANKL whole human monoclonal antibody injection) (“HLX14”) independently developed by the company were accepted by the European Medicines Agency (EMA). The indications covered by these two marketing authorization applications (MaaS) are all indications that Prolia and Xgeva (desumab) have been approved for marketing in the EU, including: (1) post-menopausal women with a high risk of fractures; and
[Hong Kong Stock Connect] Fosun Pharmaceuticals (02196) fell 3.66%. Affiliated Fuhong Hanlin (02696) may be involved in the transaction
Jinwu Financial News | Fosun Pharmaceuticals (02196)'s stock price performance was weak and remained low in the afternoon. As of press release, it reported HK$12.62, down 3.66%, and had a turnover of HK$66.1667 million. The company announced that its subsidiary Fuhong Hanlin (02696) is considering a transaction which may involve Fuhong Hanlin under Hong Kong's “Code of Corporate Takeovers and Mergers”. Currently, Fuhong Hanlin's trading is still suspended.
Henlius Biotech H Shares Trading Halted
Fu Hong Hanlin (02696.HK) suspended trading for a short time this morning
Gelonghui May 23 丨 Fu Hong Han Lin (02696.HK) announced that the company's H shares will temporarily stop trading at 9:00 a.m. today (23/5/2024).
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Low P/S No Reason For Excitement
With a price-to-sales (or "P/S") ratio of 1.8x Shanghai Henlius Biotech, Inc. (HKG:2696) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in Hong
Henlius Biotech Gets China Approval for New Indications of Arthritis Drug
Shanghai Henlius Biotech's (HKG:2696) supplemental applications for new indications of Handayuan (adalimumab injection) have been approved by China's National Medical Products Administration. The supp
Henlius Biotech Amends License Deals With Palleon for Bifunctional Protein Products
Shanghai Henlius Biotech (HKG:2696) amended a 2022 license agreement with Palleon Pharmaceuticals for two of Palleon's bifunctional fusion protein products, according to a Tuesday filing with the Hong
Henlius Biotech Expands HANDAYUAN Indications
Fu Hong Han Lin (02696.HK): A supplementary application for new indications of Handayuan (adalimumab injection) was approved by the State Drug Administration
Gelonghui, May 22丨Fu Hong Han Lin (02696.HK) announced that recently, the company's self-developed supplementary application for the addition of four additional indications of polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and Crohn's disease in children was approved by the National Drug Administration (“NMPA”). According to reports, Handayuan (adalimumab injection) is an adalimumab biosimilar drug independently developed by the company. It was approved by the NMPA for marketing in China in December 2020 (excluding Hong Kong, Macao and Taiwan regions, same below). As of the announcement date
Changes in Hong Kong stocks | Fu Hong Han Lin (02696) rose more than 4% in the afternoon. The company will release the latest HLX22 research results, trastuzumab approved for listing by the US FDA
The Zhitong Finance App learned that Fu Hong Han Lin (02696) rose more than 4% in the afternoon. As of press release, it had risen 4.78% to HK$18.86, with a turnover of HK$17.722,400. According to the news, according to Fuhong Hanlin's official account, the 2024 European Society of Oncology Gastrointestinal Oncology Symposium will be held in Munich, Germany from June 26 to 29. During this conference, Professor Li Jin of Shanghai Oriental Hospital acted as the main researcher, an innovative anti-HER2 monoclonal antibody HLX22 combined with Han Quyou (HLX02, trastuzumab) and chemotherapy for first-line treatment of locally advanced or metastatic HER2 positives
Shanghai Henlius Biotech Revises Palleon Pharma Deal
Analysis
Price Target
No Data
